1. Market Research
  2. > Pharmaceutical Market Trends
  3. > China Pharmaceuticals and Healthcare Report Q3 2016

China Pharmaceuticals and Healthcare Report Q3 2016

  • May 2016
  • -
  • Business Monitor International
  • -
  • 161 pages

Includes 3 FREE quarterly updates

BMI View: Ongoing challenges facing multinational pharmaceutical firms in China will persist into 2016.This includes pricing pressures on off-patented pharmaceuticals, as authorities look to meet the unmetmedical need in the country by expanding access to medicines while curbing rising healthcare costs. Longand uncertain drug approval times will also remain a factor impinging on sales growth, as time is needed forauthorities to fully develop and implement regulatory reforms.

Headline Expenditure Projections

- Pharmaceuticals: CNY687bn (USD109bn) in 2015 to CNY770bn (USD115bn) by 2016; +12% in localcurrency terms and +6% in USD terms.

- Healthcare: CNY4,023bn (USD640bn) in 2015 to CNY4,628bn (USD686bn) in 2015; +13.5% in localcurrency and +11.2% in USD terms.

Table Of Contents

China Pharmaceuticals and Healthcare Report Q3 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (China 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (China 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (China 2012-2020) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (China 2012-2020) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (China 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (China 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (China 2012-2020) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (China 2012-2020) 24
OTC Medicine Market Forecast 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (China 2012-2020) 27
Pharmaceutical Trade Forecast 28
Table: Pharmaceutical Trade Data And Forecasts (China 2014-2020) 30
Table: Pharmaceutical Trade Data And Forecasts local currency (China 2014-2020) 30
Industry Risk/Reward Index 31
Asia Pacific Risk/Reward Index - Q3 2016 31
China Risk/Reward Index 37
Rewards 37
Risks 37
Regulatory Review 39
Regulatory Regime 39
Table: Important China GMP Deadlines 43
Intellectual Property Issues 45
Pricing Regime 51
Reimbursement Regime 56
China - 13th Five-Year Plan To Reinforce Existing Trends 59
Market Overview 63
Healthcare Sector 63
Table: Healthcare Resources (China 2010-2015) 66
Table: Healthcare Personnel (China 2010-2015) 66
Table: Healthcare Activity (China 2010-2015) 67
Research and Development 74
Table: Selected List Of MNC With RandD Bases In China 75
Table: Selected List Of Collaboration In RandD Operations In China 78
Clinical Trials 79
Epidemiology 80
Table: Estimated Number Of New Cases Of Cancer In China 83
Competitive Landscape 84
Research-Based Industry 84
Table: Companies Represented by RDPAC 84
Table: Multinational Market Activity 85
Generic Drugmakers 86
Table: Top 20 China/Hong Kong-Based Pharmaceutical Companies According To Market Capitalisation 87
Pharmaceutical Distribution 87
Company Profile 89
AstraZeneca 89
Bayer 94
China Shijiazhuang Pharmaceutical Group 98
Eli Lilly 100
GlaxoSmithKline 104
North China Pharmaceutical Corporation 109
Novartis 112
Merck and Co 116
Merck KGaA 119
Pfizer 122
Roche 125
Sanofi 129
Shanghai Pharmaceutical 133
Sinopharm 136
13th Five Year Plan 139
13th Five-Year Plan: Key Points 139
Summary Of Contents 139
Chapter 1: Overview 140
Table: Targets 140
Chapter 2: Innovation To Drive Development 141
Chapter 3: Economic Institutions 142
Chapter 4: Modernisation Of The Agricultural Sector 143
Chapter 5: Industries 144
Chapter 6: Expand The Network Economy 145
Chapter 7: Build A Modern Infrastructure Network 145
Chapter 8: New-Type Urbanisation 146
Chapter 9: Coordination Of Regional Development 147
Chapter 10: Environmental Protection 148
Chapter 11: Continue Opening Up 148
Others: 148
Demographic Forecast 150
Table: Population Headline Indicators (China 1990-2025) 151
Table: Key Population Ratios (China 1990-2025) 151
Table: Urban/Rural Population and Life Expectancy (China 1990-2025) 152
Table: Population By Age Group (China 1990-2025) 152
Table: Population By Age Group % (China 1990-2025) 153
Glossary 155
Methodology 157
Pharmaceutical Expenditure Forecast Model 157
Healthcare Expenditure Forecast Model 157
Notes On Methodology 158
Risk/Reward Index Methodology 159
Index Overview 160
Table: Pharmaceutical Risk/Reward Index Indicators 160
Indicator Weightings 161

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.